Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Infectious Disease
•
Pulmonology
•
Hospital Medicine
•
General Hospital Medicine
How do you advise using Mycoplasma antibody testing to guide antibiotic selection in patients with pneumonia?
Related Questions
How do you weigh the risk of urinary catheter or fecal management system placement with that of soiling sacral wounds?
How do you decide on supportive care vs empiric antibiotics in a patient with suspected aspiration pneumonitis (i.e., witnessed macroaspiration event within the past 24 hours) but with features that could suggest pneumonia (e.g., acute respiratory distress, fever, leukocytosis, pulmonary infiltrates, etc.)?
How do you decide when to initiate antibiotics for superimposed bacterial pneumonia in patients with influenza?
Do you always stop dexamethasone at discharge for patients admitted with COVID requiring respiratory support (as done in the RECOVERY trial), or are there situations in which you will prescribe it to complete a 10-day course?
How do you consider sending fungal studies in a patient with pneumonia?
What is your preferred laboratory test to assess treatment response or infection resolution in patients with bacterial pneumonia?
When do you recommend limited or targeted respiratory pathogen testing versus a full respiratory pathogen panel in a patient presenting with URI symptoms?
Do you use MRSA nares PCR to influence antibiotic selection for non-respiratory infections?
Do you routinely discontinue atypical coverage in community-acquired pneumonia when PCR testing (i.e., respiratory pathogen panel) is negative for atypical organisms?
When can we consider deferring an insulin drip in patients with hypertriglyceridemia-induced pancreatitis?
